# To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

> **NCT01249651** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 101 (actual)

## Conditions studied

- Heartburn

## Interventions

- **DRUG:** esomeprazole 40 mg

## Key facts

- **NCT ID:** NCT01249651
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2012-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01249651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01249651, "To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01249651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*